HeartBeam, Inc. reported that President Robert Paul Eno received an option grant covering 55,172 shares of common stock at an exercise price of $1.45 per share. The award, granted on February 9, 2026, vests half on March 31, 2026 and the remainder on June 30, 2026, and expires on January 1, 2036. These options were issued under the company’s 2022 Equity Incentive Plan and represent equity-based compensation rather than an open-market stock purchase.
HeartBeam, Inc. is a development-stage medical technology company focused on portable, cable‑free 12‑lead ECG systems for ambulatory cardiac monitoring. Its HeartBeam System, a credit card–sized 3D ECG device with cloud software and physician portal, received FDA clearance for arrhythmia assessment in December 2024 and for 12‑lead synthesis software in December 2025.
The company generated no revenue in 2025 and had 16 employees as of December 31, 2025, growing to 17 in early 2026 with the hire of a Chief Commercial Officer to lead commercialization. Management and the auditor highlight substantial doubt about HeartBeam’s ability to continue as a going concern, citing limited working capital and the need for additional financing, which may be dilutive.
HeartBeam plans a limited U.S. launch in early 2026 targeting concierge and preventive cardiology practices, while pursuing expanded indications such as heart attack detection, an extended‑wear 12‑lead patch, and AI‑based diagnostic algorithms. The company operates in a large, growing cardiac monitoring market and reports a broad patent portfolio, including 25 issued patents worldwide and multiple pending applications protecting its 3D ECG, patch, smartwatch and AI technologies.